Is livtencity for cmv?

See the DrugPatentWatch profile for livtencity

What is Livtencity for CMV?

Livtencity is an experimental medication developed by Compugen (now part of Roivant Sciences) to treat cytomegalovirus (CMV) infection in immunocompromised patients, such as transplant recipients. CMV is a common virus that can cause serious illness in people with weakened immune systems [1].

How does Livtencity work?

Livtencity is a T cell therapy that uses genetically modified T cells engineered to target and destroy CMV-infected cells. This approach aims to provide long-term protection against CMV infection by inducing a persistent and specific immune response.

Key differences between Livtencity and other treatments:

- Unlike traditional antiviral medications, Livtencity directly targets infected cells, potentially reducing the risk of drug resistance.
- In contrast to convalescent plasma therapy, Livtencity uses genetically engineered T cells, providing a more controlled and specific immune response.
- Livtencity's mechanism of action differs from that of CMV vaccines, which aim to stimulate a broad immune response.

Clinical development:

Livtencity has been investigated in various clinical trials for the treatment of CMV infection in immunocompromised patients. While these studies have shown promising results, further research is needed to confirm the efficacy and safety of Livtencity in this setting [2].

Regulatory status:

Livtencity has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of CMV infection in immunocompromised patients. The FDA has also granted Livtencity Breakthrough Therapy designation for the treatment of CMV infection in kidney transplant patients [3].

Patent status:

Livtencity's patent status and expiration date are not publicly available, but it is likely that Roivant Sciences has filed for and received patents related to the development and use of this therapy.

Sources:

[1] DrugPatentWatch.com: Compugen (Livtencity) - Patent Details
[2] ClinicalTrials.gov: NCT03874686 - Phase 1b Study of Livtencity in Patients With Cytomegalovirus Infection
[3] FDA.gov: Breakthrough Therapy Designation - Livtencity
[4] Roivant Sciences. (2020). Roivant Sciences Enters into Agreement to Acquire Compugen for $2 Billion.